Dietary Polyphenols and Insulin Sensitivity in Overweight and Obese Humans

September 3, 2018 updated by: Maastricht University Medical Center

Long-term Supplementation of Dietary Polyphenols as Modulators of Lipid Oxidation and Mitochondrial Function in Overweight Volunteers

In this double-blind, randomized, placebo-controlled study, we aim to investigate the effects of a long-term supplementation on insulin sensitivity, mitochondrial function and substrate metabolism in healthy overweight men and women.

In each group, 21 subjects consume 100mg Resveratrol (RSV) and 150mg Epigallocatechin-gallate (EGCG), respectively Placebo capsules, twice daily over a period of 12 weeks. The subjects receive the capsules after the last pre-measurement and continue to take them throughout the post-measurements.

Before and after the supplementation period, we perform a hyperinsulinemic-euglycemic clamp with a glucose-tracer infusion to assess hepatic and systemic insulin sensitivity. Simultaneously, substrate oxidation is measured throughout the clamp by indirect calorimetry. Furthermore, we perform a high-fat mixed meal test, in which we collect blood and measure substrate oxidation during fasted and postprandial conditions. During the meal tests, extra plasma is collected at the start (t=-30) and the end (t=240), of which the supernatant is stored in light-protected tubes (EGCG is mixed 1:1 with an EGCG buffer) for analyzing polyphenol concentrations in the blood.

In the male subgroup (21 men), we additionally place each 2 microdialysis probes in the subcutaneous adipose tissue and the gastrocnemius in order to assess local lipolysis and blood flow by means of ethanol infusion.

Furthermore, a dexa-scan is performed to assess body composition and biopsies are taken under fasted conditions from the subcutaneous adipose tissue and the quadriceps femoralis muscle. These samples are stored at -80C. Part of the adipose tissue samples is collected to measure adipocyte size. Of the skeletal muscle biopsy, one part is directly buffered and used for the oxygraph to measure mitochondrial function.

At last, feces samples are collected before and after the intervention in order to assess energy content, microbial composition and short-chain fatty acid content.

Based on previous human studies in our and other departments, we hypothesize that after 12 weeks of the combined polyphenol supplementation, insulin sensitivity and mitochondrial function improve. Furthermore, based on results of a short-term study performed by our group, that demonstrated an increase in energy expenditure, a positive effect on the regulation of body composition might be expected.

Study Overview

Study Type

Interventional

Enrollment (Actual)

42

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Maastricht, Netherlands, 6229 ER
        • Maastricht University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 50 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Overweight men and women (BMI≥25kg/m2-39.9kg/m2),
  • Aged 20-35 and 35-50 years
  • Caucasian
  • Normal fasting glucose (< 6.1 mmol/L) and normal postprandial glucose (2h-glucose <7.8 mm)
  • Normal blood pressure (systolic blood pressure 100-140 mmHg, diastolic blood pressure 60-90 mmHg)
  • Weight stable in last 3 months (± 2kg)

Exclusion Criteria:

  • Women lactating, pregnant or (post) menopausal
  • Regular smokers
  • People with intensive fitness training, eg. athletes (≥ 3 per week ≥ 1 hour training)
  • Habitual consumption of green tea (more than 1 cup per day) or products containing green tea extract
  • Total caffeine consumption > 300 mg/day (1 can of cola or 2 cups of regular coffee or 2 cups of black tea or 1 cup of coffee and 1 cup of black tea or other combinations)
  • Alcohol intake >20 g/day (2 glasses of beer or wine)
  • Any dietary vitamins or dietary supplements
  • Diabetes mellitus (defined as FPG ≥ 7.0 mmol/l and/or 2hPG ≥ 11.1 mmol/l)
  • Serious pulmonary, cardiovascular, hepatic or renal disease
  • History of cardiovascular disease
  • All other relevant medical disorders that potentially interfere with this trial (e.g. history of gastro-intestinal, liver or thyroid disorders)
  • Current use of medication interfering with study intervention or interfering with study endpoints/hypotheses (e.g. medication containing caffeine like analgesics, anorectics and analeptics)
  • Not to be able to understand the study information
  • Subjects on a special diet or vegetarian
  • Blood donation 2 months prior to the study and during the study
  • Participation in other studies
  • Drug use
  • Coagulation disorders (i.e. hemophilia (type A, B and C), von Willebrand disease, vitamin K deficiency, afibrinogenemia, disseminated intravascular coagulation and thrombosis)
  • Use of anti-coagulant medication
  • Acute or history of gastrointestinal diseases (Morbus Crohn, Colitis Ulcerosa)
  • Intake of Antibiotics for the last 3 months

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo
micro-cellulose-filled Placebo
Active Comparator: EGCG+RSV-supplementation
EGCG+RSV: 300mg/d + 80mg/d
Teavigo (~300mg/d) Resveratrol (~80mg/d)
Other Names:
  • Teavigo, Pure Encapsulations Inc. (Massachusetts, USA)
  • Resveratrol, Pure Encapsulations Inc. (Massachusetts, USA)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Systemic insulin sensitivity
Time Frame: change from week 0 to week 12 after supplementation
hyperinsulinemic euglycemic clamp with glucose-tracer
change from week 0 to week 12 after supplementation

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
skeletal muscle mitochondrial function
Time Frame: change from week 0 to week 12 after supplementation
ex vivo skeletal muscle respiratory capacity
change from week 0 to week 12 after supplementation

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
lipid oxidation
Time Frame: change from week 0 to week 12 after supplementation
fasting and 4-h postprandial (high-fat mixed-meal) by indirect calorimetry
change from week 0 to week 12 after supplementation
skeletal muscle and adipose tissue lipolysis
Time Frame: change from week 0 to week 12 after supplementation
microdialysate sample fasting and postprandial (after high-fat mixed-meal)
change from week 0 to week 12 after supplementation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Ellen E Blaak, Prof., Maastricht University Medical Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2012

Primary Completion (Actual)

May 1, 2014

Study Completion (Actual)

September 1, 2014

Study Registration Dates

First Submitted

August 20, 2013

First Submitted That Met QC Criteria

March 2, 2015

First Posted (Estimate)

March 6, 2015

Study Record Updates

Last Update Posted (Actual)

September 5, 2018

Last Update Submitted That Met QC Criteria

September 3, 2018

Last Verified

September 1, 2018

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on Placebo

Subscribe